Characteristic | Treatment, No. (%) | ||
---|---|---|---|
Total (N = 1,684) | Surgery (N = 1,262) | SBRT (N = 422) | |
Mean age, years | 82.3 ± 2.5 | 82.0 ± 2.2 | 83.2 ± 3.1 |
Sex | |||
Male | 1,207 (71.7) | 904 (71.6) | 303 (71.8) |
Female | 477 (28.3) | 358 (28.4) | 119 (28.2) |
Chemotherapya | |||
No | 1,540 (91.4) | 1,152 (91.3) | 388 (91.9) |
Yes | 144 (8.6) | 110 (8.7) | 34 (8.1) |
Year of treatment | |||
2008 | 64 | 58 (90.6) | 6 (9.4) |
2009 | 83 | 72 (86.7) | 11 (13.3) |
2010 | 105 | 89 (84.8) | 16 (15.2) |
2011 | 111 | 90 (81.1) | 21 (18.9) |
2012 | 186 | 139 (74.7) | 47 (25.3) |
2013 | 219 | 154 (70.3) | 65 (29.7) |
2014 | 255 | 188 (73.7) | 67 (26.3) |
2015 | 297 | 212 (71.4) | 85 (28.6) |
2016 | 364 | 260 (71.4) | 104 (28.6) |
Follow-up, months | |||
Median | 19.4 | 20.4 | 16.8 |
IQR | 7.2–36.5 | 7.4–40.3 | 6.8–30.0 |
Median OS, months | |||
Median | 49.8 | 56.4 | 35.5 |
95% CI | 44.7–56.3 | 49.1–66.5 | 28.9–41.7 |
30-day mortality | |||
No. (%) | 36 (2.2) | 30 (2.4) | 6 (1.5) |
95% CI | 1.5–2.9 | 1.6–3.3 | 0.3–2.6 |